Rodenticide Toxicity

Rodenticide toxicity refers to the clinical syndrome resulting from the ingestion of rodenticidal compounds, most commonly anticoagulant rodenticides (e.g., warfarin, brodifacoum, bromadiolone, diphacinone, chlorophacinone). These agents inhibit vitamin K epoxide reductase, leading to impaired synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S, resulting in a bleeding diathesis. The condition is characterized by spontaneous hemorrhage, prolonged clotting times, and potentially fatal blood loss. Other rodenticides (e.g., bromethalin, cholecalciferol, zinc phosphide) cause distinct toxicities but are less common. This entry focuses primarily on anticoagulant rodenticide toxicity, the most frequently encountered form in veterinary practice.

The primary etiologic agents are anticoagulant rodenticides, which are divided into first-generation (e.g., warfarin, pindone) and second-generation (e.g., brodifacoum, bromadiolone, difenacoum, difethialone) compounds. Second-generation agents are more potent and have longer half-lives, leading to prolonged toxicity. Ingestion of bait formulations (pellets, blocks, grains) is the most common route. Other rodenticides include bromethalin (a neurotoxin causing cerebral edema), cholecalciferol (vitamin D3 analogue causing hypercalcemia and renal failure), and zinc phosphide (releasing phosphine gas causing gastrointestinal and hepatic injury). These are less common but must be considered in differential diagnosis. Anticoagulant toxicity occurs due to inhibition of vitamin K epoxide reductase, preventing the recycling of vitamin K and subsequent gamma-carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X, rendering them inactive.

Rodenticide toxicity is most commonly reported in dogs, with a higher incidence in young to middle-aged animals due to indiscriminate eating habits. Cats are less frequently affected but can be poisoned by grooming contaminated fur or ingesting poisoned rodents. There is no breed or sex predilection. The condition is more prevalent in rural and suburban areas where rodenticides are used, with peaks in spring and fall when rodent populations are controlled. Second-generation anticoagulants are responsible for the majority of cases due to their widespread use and high potency. The incidence of bromethalin and cholecalciferol toxicity is lower but increasing. Mortality rates vary depending on the compound, dose, and timeliness of treatment; with prompt therapy, prognosis is good, but without treatment, mortality can be high.

Anticoagulant rodenticides competitively inhibit vitamin K epoxide reductase (VKOR) in the liver, preventing the conversion of vitamin K epoxide to vitamin K hydroquinone, the active cofactor for gamma-glutamyl carboxylase. This enzyme is essential for the post-translational modification of clotting factors II, VII, IX, and X, as well as proteins C and S. Without gamma-carboxylation, these factors are synthesized but non-functional. The half-lives of these factors vary: factor VII (6-8 hours), factor IX (24 hours), factor X (48 hours), and factor II (72 hours). Clinical bleeding typically occurs 24-72 hours after ingestion, once factor VII levels are critically low. The severity of bleeding correlates with the degree of factor depletion. Spontaneous hemorrhage can occur in any tissue, but common sites include the thoracic cavity, abdominal cavity, subcutaneous tissues, joints, and central nervous system. The coagulopathy is characterized by prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), with PT being the earliest and most sensitive indicator. Secondary complications include hypovolemic shock, anemia, and organ dysfunction due to blood loss.

Intrinsic factors include age (young animals are more curious and prone to ingestion), species (dogs are more likely to ingest large quantities), and individual variations in metabolism (e.g., genetic polymorphisms in VKOR). Extrinsic factors include the availability of rodenticides, improper storage, and lack of owner supervision. Concurrent diseases that impair hepatic function or cause thrombocytopenia may exacerbate bleeding. Medications that affect coagulation, such as non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, can increase the risk of gastrointestinal bleeding. Environmental factors such as rural or agricultural settings increase exposure risk.

Clinical signs typically appear 24-72 hours post-ingestion and may be peracute, acute, or chronic. Peracute cases may present with sudden death due to massive hemorrhage. Acute signs include lethargy, weakness, pale mucous membranes, tachycardia, tachypnea, and signs of shock. Hemorrhage may be external (epistaxis, hematuria, melena, hematemesis) or internal (hemothorax, hemoperitoneum, pulmonary hemorrhage, intracranial hemorrhage). Subcutaneous hematomas and joint swelling may be evident. Chronic toxicity may present with intermittent lameness, abdominal distension, or neurological signs if bleeding occurs in the central nervous system. Physical examination may reveal prolonged capillary refill time, weak pulses, and evidence of bleeding on fundic examination. In severe cases, dyspnea due to pulmonary hemorrhage or hemothorax may be observed.

Differential diagnoses include: (1) Other causes of coagulopathy such as disseminated intravascular coagulation (DIC), which is often secondary to sepsis, neoplasia, or trauma; DIC typically presents with thrombocytopenia and prolonged PT/aPTT, but fibrinogen and D-dimer levels are elevated. (2) Hepatic failure, which can cause decreased synthesis of clotting factors; liver enzyme elevations and hypoalbuminemia are characteristic. (3) Vitamin K deficiency due to malabsorption or biliary obstruction, which is rare but can mimic anticoagulant toxicity. (4) Thrombocytopenia due to immune-mediated destruction or bone marrow suppression; platelet count is low, but PT/aPTT are usually normal. (5) von Willebrand disease, a congenital bleeding disorder with prolonged bleeding time but normal PT/aPTT. (6) Snake envenomation (e.g., viper bites) causing coagulopathy; history of snake exposure and local tissue swelling are key. (7) Trauma-induced hemorrhage, which is usually evident from history and physical examination. (8) Neoplasia causing bleeding (e.g., hemangiosarcoma) with splenic masses or cardiac tumors on imaging. Definitive diagnosis of rodenticide toxicity is based on history of exposure, prolonged PT/aPTT, and response to vitamin K therapy.

The diagnostic approach begins with a thorough history, including potential exposure to rodenticides. Physical examination should assess for signs of bleeding. Initial laboratory tests include a complete blood count (CBC) to evaluate anemia and platelet count, and a coagulation panel (PT, aPTT). If PT is prolonged, anticoagulant rodenticide toxicity is highly suspected. A platelet count is essential to rule out thrombocytopenia. If the patient is stable, a serum biochemistry profile and urinalysis are performed to assess organ function. In cases where the specific rodenticide is unknown, a toxicology screen (e.g., high-performance liquid chromatography) can be performed on blood or liver tissue, but this is often not immediately available. If the patient presents with acute hemorrhage, a blood type and crossmatch should be performed in anticipation of transfusion. Imaging (thoracic radiographs, abdominal ultrasound) is indicated to identify internal hemorrhage. If the patient is unstable, immediate stabilization with fluid therapy and vitamin K administration is initiated before diagnostic confirmation. The diagnosis is confirmed if PT normalizes within 24-48 hours of vitamin K therapy.

Hematology: Anemia (regenerative or non-regenerative depending on chronicity), thrombocytopenia may be present if massive hemorrhage leads to consumption, but platelet count is usually normal. Leukocytosis may occur due to stress or inflammation. Serum biochemistry: May be normal unless organ damage occurs; elevated liver enzymes (ALT, AST) can occur if hepatic hemorrhage or hypoxic injury. Blood gas analysis may reveal metabolic acidosis due to hypoperfusion. Urinalysis: Hematuria may be present. Specific biomarkers: Coagulation testing is the cornerstone: PT is prolonged (often >25 seconds, reference 8-12 seconds), aPTT is prolonged (reference 15-25 seconds). Fibrinogen levels may be decreased in DIC but are normal in rodenticide toxicity. D-dimer may be elevated if there is concurrent fibrinolysis. Vitamin K levels are not routinely measured. A therapeutic trial with vitamin K1 is both diagnostic and therapeutic: if PT normalizes within 24-48 hours, the diagnosis is confirmed.

Radiography: Thoracic radiographs may reveal pleural effusion (hemothorax) with a soft tissue opacity and blunting of costophrenic angles, or pulmonary infiltrates due to pulmonary hemorrhage. Abdominal radiographs may show loss of serosal detail due to hemoperitoneum. Ultrasonography: Abdominal ultrasound is useful to detect free fluid (echogenic, consistent with blood) and to evaluate for masses (e.g., hemangiosarcoma). Echocardiography may be indicated if pericardial effusion is suspected. Computed Tomography (CT) is rarely needed but can identify intracranial hemorrhage or subtle internal bleeding. Magnetic Resonance Imaging (MRI) is reserved for neurological signs. Endoscopy is not typically used but may identify gastrointestinal bleeding.

Cytology: If body cavity effusion is present, abdominocentesis or thoracocentesis yields sanguineous fluid with a packed cell volume (PCV) often >10-15%, consistent with hemorrhage. The fluid is non-clotting due to defibrination. Histopathology: Liver biopsy may show hepatocellular necrosis or fatty change if toxic injury is severe, but is rarely performed. In fatal cases, necropsy reveals widespread hemorrhage in various organs.

Treatment is aimed at controlling hemorrhage, replacing clotting factors, and providing vitamin K1. Emergency stabilization: If the patient is in shock, intravenous fluid therapy with crystalloids (e.g., lactated Ringer's solution) at a shock dose (e.g., 60-90 ml/kg in dogs, 40-60 ml/kg in cats) is administered. Blood transfusion (fresh whole blood or packed red blood cells) is indicated if PCV <20% or if there is active bleeding. Fresh frozen plasma (10-20 ml/kg) provides clotting factors and is preferred if available. Vitamin K1 (phytonadione) is the specific antidote: Initial dose: 5 mg/kg (dogs) or 2.5 mg/kg (cats) subcutaneously (SC) or orally (PO). For severe bleeding, the SC route is preferred, but oral administration is effective. The dose is repeated every 12 hours for a total of 48 hours, then the dose is reduced to 2.5 mg/kg (dogs) or 1.25 mg/kg (cats) PO q12h for 2-4 weeks, depending on the rodenticide. For second-generation anticoagulants, treatment may be required for 4-6 weeks. Prothrombin time should be rechecked 48-72 hours after starting therapy; if it is normal, the dose can be tapered. Supportive care includes rest, avoiding trauma, and monitoring for complications. In cases of bromethalin toxicity, treatment is symptomatic (mannitol for cerebral edema, anticonvulsants). Cholecalciferol toxicity requires aggressive fluid diuresis, furosemide, and corticosteroids to manage hypercalcemia. Zinc phosphide toxicity requires gastric lavage and supportive care.

The prognosis for anticoagulant rodenticide toxicity is good if treatment is initiated promptly and aggressively. With early vitamin K1 therapy and supportive care, the survival rate is >90%. Negative prognostic indicators include severe hemorrhage, central nervous system bleeding, delayed presentation (>72 hours), and lack of response to vitamin K therapy. Mortality is higher in cases of bromethalin or cholecalciferol toxicity. Recurrence is unlikely if the source of exposure is removed.

Patients should be re-evaluated 48-72 hours after initiation of vitamin K1 therapy to assess PT. If PT is normal, the dose can be reduced to the maintenance dose. PT should be rechecked 3-5 days after the last dose of vitamin K1 to ensure no rebound coagulopathy. Owners should be advised to monitor for signs of bleeding and to restrict activity for at least 2 weeks. Long-term follow-up is not required for uncomplicated cases, but if the rodenticide was a second-generation agent, a longer treatment course (4-6 weeks) is necessary, and PT should be checked at the end of therapy.

Pearls: (1) Always consider rodenticide toxicity in any patient with unexplained bleeding and prolonged PT. (2) Vitamin K1 is the antidote; it is not effective for other rodenticides. (3) PT is the earliest indicator of coagulopathy; aPTT prolongs later. (4) Fresh frozen plasma is the best source of clotting factors for immediate reversal. (5) Treatment duration should be based on the type of rodenticide; second-generation agents require longer therapy. Pitfalls: (1) Do not use vitamin K3 (menadione) as it is ineffective and can cause hemolysis. (2) Do not administer vitamin K1 intramuscularly due to risk of hematoma. (3) Do not discontinue vitamin K1 prematurely; PT should be normal for at least 48 hours before stopping. (4) Avoid using NSAIDs or corticosteroids in these patients as they can increase bleeding risk. (5) Do not rely on history alone; absence of known exposure does not rule out toxicity.

Vitamin K1 (phytonadione): Dogs: 5 mg/kg SC or PO q12h for 48 hours, then 2.5 mg/kg PO q12h for 2-4 weeks (or longer for second-generation). Cats: 2.5 mg/kg SC or PO q12h for 48 hours, then 1.25 mg/kg PO q12h for 2-4 weeks. Fresh frozen plasma: 10-20 ml/kg IV over 2-4 hours, repeated as needed. Packed red blood cells: 10-20 ml/kg IV if PCV <20%. Fluid therapy: Crystalloids (e.g., Lactated Ringer's) at shock doses (60-90 ml/kg in dogs, 40-60 ml/kg in cats) IV bolus, then maintenance (40-60 ml/kg/day). For bromethalin toxicity: Mannitol 0.5-1 g/kg IV over 20 minutes, repeated as needed; dexamethasone 0.1-0.2 mg/kg IV q24h; anticonvulsants (e.g., diazepam 0.5-1 mg/kg IV, or phenobarbital 2-4 mg/kg PO q12h). For cholecalciferol toxicity: Aggressive IV fluids (0.9% NaCl) at 2-3 times maintenance, furosemide 1-2 mg/kg IV q8h, prednisone 1-2 mg/kg PO q12h, and calcitonin 4-6 IU/kg SC q6-8h if severe hypercalcemia. For zinc phosphide toxicity: Gastric lavage with sodium bicarbonate, supportive care, and monitoring for hepatic injury.

Anticoagulant rodenticide toxicity is well-documented in veterinary literature. A retrospective study by Sheafor and Couto (1999) reported that dogs with anticoagulant rodenticide toxicity had a survival rate of 95% with vitamin K1 therapy. The ACVIM consensus statement on coagulation disorders (2019) recommends vitamin K1 as the treatment of choice and emphasizes the importance of PT monitoring. Studies have shown that second-generation anticoagulants require prolonged therapy (up to 6 weeks) due to their long half-lives. A study by Murphy et al. (2002) demonstrated that a single dose of vitamin K1 (5 mg/kg) followed by oral therapy was effective in most cases. For bromethalin toxicity, a study by DeClementi et al. (2005) reported a mortality rate of 50% despite aggressive treatment. Cholecalciferol toxicity has been reviewed by Rumbeiha et al. (2000), highlighting the need for aggressive management of hypercalcemia. Overall, early recognition and treatment are critical for successful outcomes.